ACTB |
Actin Beta |
AE |
Adverse effect |
AKT1 |
RAC-alpha serine/threonine-protein kinase |
ATRA |
All-trans retinoic acid |
BC |
Breast cancer |
BCC |
Breast cancer cells |
CTC |
Circulating tumor cells |
COL4A5 |
Collagen type IV alpha 5 chain |
CTNNA1 |
Catenin alpha 1 |
CTNNB1 |
Catenin beta 1 |
D |
Day |
ECM |
Extracellular matrix |
EGFR |
Epidermal growth factor receptor |
ERα |
Estrogen receptor-alpha |
ERβ1 |
Estrogen receptor-beta1 |
ERK1 |
Extracellular signal-regulated kinase 1 |
EVs |
Extracellular vesicles |
FAs |
Fibroadenomas |
FELs |
Fibro-epithelial lesions |
GRHL2 |
Grainyhead-like 2 |
Her-2 |
Human epidermal growth factor receptor 2 |
ITGB1 |
Integrin-beta1 |
MAPK14 |
Mitogen-activated protein kinase 14; p38 |
MCSs |
Multicellular spheroids |
NACT |
Neoadjuvant chemotherapy |
OHT |
4-hydroxytamoxifen |
OS |
Overall survival |
PD |
Progression of disease |
PTs |
Phyllodes tumors |
PD-L1 |
Programmed cell death ligand-1 |
RPM |
Random positioning machine |
sTILs |
Stromal tumor-infiltrating lymphocytes |
TNBC |
Triple-negative breast cancer |
TUBB |
Tubulin-beta |